Clinical trials sponsored by The First Affiliated Hospital of Nanchang University

Phase breakdown

Conditions studied

Recruiting trials led by The First Affiliated Hospital of Nanchang University

• Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
  NCT06118762 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
  NCT06751914 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
  NCT06751966 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
  NCT06751953 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations

Common questions

How many trials is The First Affiliated Hospital of Nanchang University recruiting for?

The First Affiliated Hospital of Nanchang University is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.